Summary of Major
Modifications andExplanatory Notes
2024 Prohibited List

Subclasses of sections S1, S2, S4, M1, M2, M3 and S6 of the Prohibited List wererenumbered for better clarity throughout the document to avoid any misinterpretation ofsubclasses but there was no change in classification.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES(IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES
S0. Non-Approved Substances•

2,4-Dinitrophenol (DNP) and troponin activators (e.g. Reldesemtiv and Tirasemtiv) werelisted as examples.

S1. Anabolic Agents•

Trestolone (7ɑ-methyl-19-nortestosterone, MENT), dimethandrolone (7ɑ,11ß-Dimethyl19-nortestosterone) and 11ß-methyl-19 nortestosterone were added as examples ofnandrolone (19-nortestosterone) analogues.

S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics•

S2.2.1 was reworded under the heading of “Testosterone-stimulating peptides in males”
for clarity. This specifies that buserelin, deslorelin, goserelin, histrelin, leuprorelin,nafarelin and triptorelin are examples of Gonadotrophin-Releasing Hormone (GnRH)
agonist analogues, with histrelin added as a new example.
Kisspeptin and its agonist analogues, which act to stimulate GnRH secretion, andconsequently testosterone, were also added.

•••

S2.2.2 : Tetracosactide (ACTH 1-24) was added as an example, as it is the first 24 aminoacid portion of natural corticotrophin (ACTH), and possesses the full biological activityof the natural hormone.
S2.2.4: Capromorelin and ibutamoren (MK-677) were added as examples of growth
hormone secretagogues (GHS), which are mimetics of the natural hormone, ghrelin, thatstimulates the production of growth hormone (GH) and, in turn, insulin-like growth factor
1 (IGF-1).
S2.3: The INN name for recombinant human IGF-1, mecasermin, was added.
1S4. Hormone and Metabolic Modulators•

S4.4.1 was updated to include Rev-Erb-ɑ agonists and as example, SR9011 was added
and SR9009 was relocated.

S5. Diuretics and Masking Agents•	 Editorial changes were made to section S5 to improve clarity. Conivaptan andmozavaptan were added as further examples of vaptan drugs.

2

PROHIBITED METHODS
M1. Manipulation of Blood and Blood Components•	 Donation by Athletes of plasma or plasma components by plasmapheresis is no longer
prohibited when performed in a registered collection center.

3

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITIONPROHIBITED SUBSTANCES
S6. Stimulants	2-phenylpropan-1-amine (BMPEA, ß-methylphenethylamine) was added as an example
of a specified stimulant due to its presence in dietary supplements.

•	Tramazoline was added as an imidazoline derivatives under Exceptions.

•S7. Narcotics
	Tramadol is prohibited In-Competition as of 1 January 2024 as approved by theExecutive Committee on 23 September 2022. Tramadol has been on the WADA
Monitoring Program for some years. Monitoring data has indicated significant Use insports including cycling, rugby and football. Tramadol abuse, with its dose-dependent
risks of physical dependence, opiate use disorder and overdoses in the general
population, is of concern and has led to it being a controlled drug in many countries.
Research studies funded by WADA1 have confirmed the potential for tramadol toenhance physical performance in sports. The washout period§, based on the therapeutic
use of tramadol, is established at 24 hours.

•§

1The “washout period” refers to the time from the last administered dose to the time ofthe start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before aCompetition in which the Athlete is scheduled to participate, unless a different period
was approved by WADA for a given sport).

a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol
effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial.
J Sci Med Sport. 2018 Jul;21(7):654-660.
b) Mauger L, Thomas T, Smith S, Fennell C. Tramadol is a performance-enhancing drug in highly trained cyclists: a randomized controlled trial.
J Appl Physiol. 2023 Jul;135: 467–474.

4

S9. Glucocorticoids•	The minimum washout periods following rectal administration of glucocorticoids are
now included in the Glucocorticoid Washout Table; glucocorticoids remain prohibited
In-Competition when administered by the rectal route. These washout periods are basedon the use of these medications according to the maximum manufacturer’s licensed
doses:
Route

Glucocorticoid

Washout period*

Oral**All glucocorticoids;

3 daysExcept: triamcinolone;triamcinolone acetonide

10 daysIntramuscular

Betamethasone; dexameth- 5 days
asone; methylprednisolone
Prednisolone; prednisone

10 days

Triamcinolone acetonide

60 days

Local injections (including
periarticular, intra-articular,peritendinous and intratendinous)

All glucocorticoids;

3 days

RectalAll glucocorticoids;

3 daysExcept: triamcinolone diacetate; triamcinolone acetonide

10 days

Except: prednisolone;
10 daysprednisone; triamcinolone
acetonide;
triamcinolone hexacetonide*The “washout period” refers to the time from the last administered dose to the time ofthe start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before
a Competition in which the Athlete is scheduled to participate, unless a different
period was approved by WADA for a given sport). This is to allow elimination of theglucocorticoid to below the reporting level.
** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual.
•	The Washout Period Table is also found in the List FAQ https://www.wada-ama.org/en/
prohibited-list#faq-anchor

5

MONITORING PROGRAM•

Salmeterol and vilanterol were removed as the required prevalence data were obtained.

•Tramadol was removed as it is now prohibited under S7: Narcotics .

•Tapentadol and dihydrocodeine were added to monitor patterns of use In Competition.

• he GLP-1 analogue semaglutide was added to examine the prevalence and pattern ofTuse in sport.

* 	For further information on previous modifications and clarifications, please consult
the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/
prohibited-list#faq-anchor.

6